Swipe om te navigeren naar een ander artikel
The online version of this article (https://doi.org/10.1007/s11136-018-1925-1) contains supplementary material, which is available to authorized users.
In order to address the current deficiency of health utility evidence relevant for economic evaluations involving treatments for rheumatoid arthritis (RA) in the Chinese setting, this study aims to develop a mapping algorithm linking the Health Assessment Questionnaire (HAQ) and EQ-5D-5L in a Chinese population of patients with RA.
An estimation sample was obtained from a cross-sectional study that collected HAQ, the pain Visual Analogue Scale, and EQ-5D-5L in RA patients in two tertiary referral hospitals in China. Mapping algorithms were derived in this study using two alternative regression methods: the beta regression and a multivariate ordered probit regression. The internal validity of the mapping algorithms was assessed in each case by calculating predictive performance using a bootstrapping procedure.
Of the several algorithms developed using these data, predictive performance was shown to be better when VAS pain was included as a predictor and when the multivariate ordered probit regression method was used, rather than the beta regression method. The algorithms developed were shown to be comparable, in terms of predictive performance, to existing mapping studies despite the small sample size of the estimation data.
It is hoped that the availability of these algorithms will facilitate the development of cost-effectiveness studies evaluating RA treatments in the Chinese health care setting.
Silman, A. J., & Hochberg, M. C. (2001). Epidemiology of the rheumatic diseases (2nd edn.). Oxford: Oxford University Press.
China Health Statistical Yearbook 2012. 2012. Chinese Center for Disease Control and Prevention: Beijing.
Documentation of the Second China National Samples Survey on Disability. 2007, China Statistics Press.
International Society for Pharmacoeconomics and Outcomes Research. Pharmacoeconomic guidelines around the world: China. 2011. Retrieved March 12, 2017, from https://www.ispor.org/PEguidelines/COUNTRYSPECIFIC.asp.
Wu, B., Wilson, A., Wang, F. F., et al. (2012). Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china. PLoS ONE, 7(10), e47373. CrossRef
Zhang, Y., Yang, L., Dong, P., Xie, X., & Tang, B. (2012). PMS14 cost-effectiveness analysis of etanercept in the treatment of rheumatoid arthritis in China. Value in Health, 15(7), A673. CrossRef
Fries, J. F., Spitz, P., Kraines, R. G., & Holman, H. R. (1980). Measurement of patient outcome in arthritis. Arthritis & Rheumatology, 23(2), 137–145. CrossRef
The EuroQol Group. (1990). EuroQol—A new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208. CrossRef
Ariza-Ariza, R., Hernández-Cruz, B., Carmona, L., et al. (2006). Assessing utility values in rheumatoid arthritis: A comparison between time trade-off and the EuroQol. Arthritis Care & Research, 55(5), 751–756. CrossRef
Witney, A. G., Treharne, G. J., Tavakoli, M., et al. (2006). The relationship of medical, demographic and psychosocial factors to direct and indirect health utility instruments in rheumatoid arthritis. Rheumatology, 45(8), 975–981. CrossRef
Bansback, N., Marra, C., Tsuchiya, A., et al. (2007). Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis Care & Research, 57(6), 963–971. CrossRef
Lillegraven, S., Kristiansen, I. S., & Kvien, T. K. Comparison of utility measures and their relationship with other health status measures in 1041 patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2010 69:1762–1767 CrossRef
Wolfe, F., Michaud, K., & Wallenstein, G. (2010). Scale characteristics and mapping accuracy of the US EQ-5D, UK EQ-5D, and SF-6D in patients with rheumatoid arthritis. The Journal of Rheumatology, 37(8), 1615–1625. CrossRef
Carreño, A., Fernández, I., Badia, X., et al. (2011). Using HAQ-DI to estimate HUI-3 and EQ-5D utility values for patients with rheumatoid arthritis in Spain. Value in Health, 14(1), 192–200. CrossRef
Alava, M. H., Wailoo, A., Wolfe, F., & Michaud, K. (2013). The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis. Rheumatology, 52(5), 944–950. CrossRef
Kontodimopoulos, N., Bozios, P., Yfantopoulos, J., & Niakas, D. (2013). Longitudinal predictive ability of mapping models: Examining post-intervention EQ-5D utilities derived from baseline MHAQ data in rheumatoid arthritis patients. The European Journal of Health Economics, 14(2), 307–314. CrossRef
Hoshi, D., Tanaka, E., Igarashi, A., et al. (2016). Profiles of EQ-5D utility scores in the daily practice of Japanese patients with rheumatoid arthritis; Analysis of the IORRA database. Modern Rheumatology, 26(1), 40–45. CrossRef
Kim, H. L., Kim, D., Jang, E. J., et al. (2016). Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data. Rheumatology International, 36(4), 505–513. CrossRef
Nair, S. C., Welsing, P. M., Marijnissen, A. K., et al. (2015). Does disease activity add to functional disability in estimation of utility for rheumatoid arthritis patients on biologic treatment? Rheumatology, 55, 94. CrossRef
Malottki, K., Barton, P., Tsourapas, A., et al. (2011). Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: A systematic review and economic evaluation. Health Technology Assessment, 15(14).
Norman, R., Cronin, P., Viney, R., et al. (2009). International comparisons in valuing EQ-5D health states: A review and analysis. Value in Health, 12(8), 1194–1200. CrossRef
Pennington, B., & Davis, S. (2014). Mapping from the Health Assessment Questionnaire to the EQ-5D: The impact of different algorithms on cost-effectiveness results. Value in Health, 17(8), 762–771. CrossRef
An, Y., Liu, T., He, D., Wu, L., Li, J., Liu, Y., et al. (2017). The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: A real-world large scale study. Clinical Rheumatology, 36(1), 35–43. CrossRef
Li, Z., Zhang, F., Kay, J., Fei, K., Han, C., Zhuang, Y., Wu, Z., & Hsia, E. C. (2016). Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy. International Journal of Rheumatic Diseases, 19(11), 1143–1156. CrossRef
Kremer, J. M., Blanco, R., Brzosko, M., Burgos-Vargas, R., Halland, A. M., Vernon, E., Ambs, P., & Fleischmann, R. (2011). Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis & Rheumatology, 63(3), 609–621. CrossRef
US National Library of Medicine. Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China. Retrieved February 18, 2018, from https://clinicaltrials.gov/ct2/show/NCT02668640.
Hu, H., Luan, L., Yang, K., & Li, S. C. (2016). Psychometric validation of Chinese Health Assessment Questionnaire for use in rheumatoid arthritis patients in China. International Journal of Rheumatic Diseases, 20, 1987–1992. CrossRef
Fries, J. F., Spitz, P. W., & Young, D. Y. (1981). The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. The Journal of Rheumatology, 9(5), 789–793.
Hochberg, M. C., Chang, R. W., Dwosh, I., Lindsey, S., Pincus, T., & Wolfe, F. (1992). The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis & Rheumatism, 35(5)(1), 498–502. CrossRef
Wang, G., Mu, R., & Xu, H. (2015). Management of rheumatoid arthritis in People’s Republic of China—Focus on tocilizumab and patient considerations. International Journal of General Medicine, 8, 187–194. CrossRef
Herdman, M., Gudex, C., Lloyd, A., et al. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727–1736. CrossRef
Luo, N., Liu, G., Li, M., et al. (2017). Estimating an EQ-5D-5L value set for China. Value in Health, 20, 662–669. CrossRef
Janssen, M. F., Bonsel, G. J., & Luo, N. (2018). Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries. PharmacoEconomics, 36, 675–697. CrossRef
Dakin, H. (2013). Review of studies mapping from quality of life or clinical measures to EQ-5D: An online database. Health and Quality of Life Outcomes, 11(1), 151. CrossRef
Longworth, L., & Rowen, D. (2011). The use of mapping methods to estimate health state utility values. NICE DSU Technical Support Document 10.
Austin, P. C. (2002). A comparison of methods for analyzing health-related quality-of-life measures. Value in Health., 5(4), 329–337. CrossRef
Chuang, L. H., & Kind, P. (2009). Converting the SF-12 into the EQ-5D. Pharmacoeconomics, 27(6), 491–505. CrossRef
Alava, M. H., Wailoo, A. J., & Ara, R. (2012). Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value in Health, 15(3), 550–561. CrossRef
Basu, A., & Manca, A. (2012). Regression estimators for generic health-related quality of life and quality-adjusted life years. Medical Decision Making, 32(1), 56–69. CrossRef
Hunger, M., Döring, A., & Holle, R. (2012). Longitudinal beta regression models for analyzing health-related quality of life scores over time. BMC Medical Research Methodology, 12(1), 144. CrossRef
Gray, A. M., Rivero-Arias, O., & Clarke, P. M. (2006). Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Medical Decision Making, 26(1), 18–29. CrossRef
Van Hout, B., Janssen, M. F., Feng, Y. S., et al. (2012). Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value in Health, 15(5), 708–715. CrossRef
Hernández Alava, M., Wailoo, A., Wolfe, F., & Michaud, K. (2014). A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes. Medical Decision Making, 34(7), 919–930. CrossRef
Conigliani, C., Manca, A., & Tancredi, A. (2015). Prediction of patient-reported outcome measures via multivariate ordered probit models. Journal of the Royal Statistical Society: Series A (Statistics in Society), 178(3), 567–591. CrossRef
Research Councils, U. K. Modelling generic preference based outcome measures—Development and comparison of methods. Retrieved June 26, 2017, from http://gtr.rcuk.ac.uk/project/5A46044C-DC5B-4A0D-B21E-863FCFF87114.
Zeileis, A., Cribari-Neto, F., Gruen, B., et al. Package ‘betareg’.
Hirk, R., Hornik, K., & Vana, L. (2017). mvord: An R Package for Fitting Multivariate Ordinal Regression Models.
Madan, J., Ades, T., Barton, P., et al. (2015). Consensus decision models for biologics in rheumatoid and psoriatic arthritis: Recommendations of a multidisciplinary working party. Rheumatology and Therapy, 2(2), 113–125. CrossRef
Le, Q. A., & Doctor, J. N. (2011). Probabilistic mapping of descriptive health status responses onto health state utilities using Bayesian networks: an empirical analysis converting SF-12 into EQ-5D utility index in a national US sample. Medical Care, 49, 451–460. CrossRef
Steyerberg, E. (2008). Clinical prediction models: a practical approach to development, validation, and updating. New York: Springer.
Thorat, T., Lin, P. J., & Neumann, P. J. (2015). The state of cost-utility analyses in Asia: A systematic review. Value in Health Regional Issues, 6, 7–13. CrossRef
Kennedy-Martin, T., Mitchell, B. D., Boye, K. S., et al. (2014). The health technology assessment environment in mainland China, Japan, South Korea, and Taiwan—Implications for the evaluation of diabetes mellitus therapies. Value in Health Regional Issues, 3, 108–116. CrossRef
Chen, Y., Banta, D., & Tang, Z. (2009). Health technology assessment development in China. International Journal of Technology Assessment in Health Care, 25(S1), 202–209. CrossRef
- Mapping between HAQ-DI and EQ-5D-5L in a Chinese patient population
- Springer International Publishing